Immunocore Holdings plc (IMCR)
NASDAQ: IMCR · Real-Time Price · USD
29.02
-0.08 (-0.27%)
Jan 17, 2025, 4:00 PM EST - Market closed
Immunocore Holdings Employees
Immunocore Holdings had 497 employees as of December 31, 2023. The number of employees increased by 89 or 21.81% compared to the previous year.
Employees
497
Change (1Y)
89
Growth (1Y)
21.81%
Revenue / Employee
$596,201
Profits / Employee
-$94,660
Market Cap
1.45B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
IMCR News
- 10 days ago - Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 14 days ago - Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 18 days ago - Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development - GlobeNewsWire
- 4 weeks ago - Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME - GlobeNewsWire
- 7 weeks ago - Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma - GlobeNewsWire
- 2 months ago - Immunocore to present at upcoming investor conferences - GlobeNewsWire
- 2 months ago - Immunocore reports third quarter financial results and provides a business update - GlobeNewsWire
- 4 months ago - Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer - GlobeNewsWire